-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BRIEF-Fosun Pharma And Henlius Entered Into An Exclusive License Agreement For Serplulimab In The US

Reuters · 01/07/2023 04:35
BRIEF-Fosun Pharma And Henlius Entered Into An Exclusive License Agreement For Serplulimab In The US

- Shanghai Fosun Pharmaceutical 600196.SS

  • FOSUN PHARMA AND HENLIUS ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT FOR SERPLULIMAB IN THE US

Source text for Eikon: ID:

Further company coverage: 2696.HK


((Reuters.Brief@thomsonreuters.com;))